FDA Export Reform

HEHS-96-60R: Published: Dec 21, 1995. Publicly Released: Dec 21, 1995.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO reviewed proposed drug export legislation that would allow the export of drugs not approved by the Food and Drug Administration (FDA), focusing on the: (1) criteria that Congress could use to identify whether countries have adequate drug regulatory systems; and (2) implications of applying those criteria to other countries. GAO noted that: (1) the World Health Organization's (WHO) existing information system is adequate to identify criteria to assess countries' pharmaceutical regulatory systems; (2) countries that meet the export criteria should have adequate drug laws and regulatory bodies that oversee pharmaceutical activities, a drug registry, and drug quality assurance and adverse drug reaction (ADR) systems; (3) most of the countries with the largest economies meet the export criteria, but many do not have formal ADR systems; (4) most countries rely on the exporting country's regulatory authority to certify an exported drug's registration and sales authorization because they lack a comprehensive quality assurance system; (5) since non-FDA approved drugs are not freely marketed in the United States, non-tier I importing countries will have to rely on their own or other countries' quality assurance systems; and (6) WHO will complete 2 additional studies that will provide further information on countries' drug regulatory systems and identify essential evaluation criteria.

Aug 15, 2018

Aug 13, 2018

Aug 10, 2018

Jul 31, 2018

Jul 26, 2018

Jul 18, 2018

Jul 17, 2018

Jul 11, 2018

Jul 2, 2018

Jun 28, 2018

Looking for more? Browse all our products here